Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and AbbVie Inc. (NYSE:
ABBV) today announced that they have entered into a global collaboration
to develop and commercialize duvelisib (IPI-145), Infinity’s oral
inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for
the treatment of patients with cancer.
- Infinity to Receive $275 Million Upfront Payment and $530 Million in Potential Milestones - - Companies to Jointly Develop and Commercialize Duvelisib in U.S., with Equal Profit Share; Infinity to Receive Royalties on Sales Outside the U.S. -
- Infinity to Host Conference Call Today at 8:30 A.M. ET/7:30 A.M. CT - CAMBRIDGE, Mass.
Service Will Feature Blockbuster Lionsgate Films Such As Divergent and The Twilight Saga: Eclipse and Premium TV Programming Including Mad Men, Weeds, Nashville, The Royals and Rosemary's Baby
HANGZHOU, China and SANTA MONICA, Calif.
- Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union - Driven by positive Phase 2 results with Cimzia® in psoriasis and the Phase 3 results in psoriatic arthritis(1,2)
- Subject to regulatory approval in psoriasis, Dermira is granted exclusive rights to market Cimzia® to dermatologists in the US and Canada BRUSSELS and REDWOOD CITY, Calif.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.